Shyama Computro. (531219)

Score breakdown: P/E: 1/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Trades at a deep discount to book value: P/B of 0.48 against book value of ₹11.18.
• Piotroski F-Score of 7/9 suggests the balance sheet is not showing acute financial distress.
• Zero reported sales/profit growth means there is no sudden collapse in the headline numbers, though activity is negligible.
• Small market cap of ₹6 crore may allow a large pharmaceutical order or restructuring to have an outsized effect, if one materialises.

Concerns

• Latest quarter shows ₹0 sales and ₹0 net profit, indicating no active operating earnings.
• ROE of 2.07% and ROCE of 1.00% are far below acceptable return levels for a viable business.
• P/E of 20.11 on zero-growth earnings is unjustified; the PEG of 0.20 is misleading when growth is 0.00%.
• Promoter holding and debt/equity data are unavailable, creating a serious transparency problem for retail investors.

AI Analysis

At first glance, Shyama Computro tempts the bargain hunter: ₹5.40 against book value of ₹11.18, a 52% discount. But Benjamin Graham taught me that a low price-to-book is only interesting if the assets are real and earning power backs them. Here the earning engine is silent. Sales growth and profit growth are both zero, and the latest quarter shows ₹0 sales and ₹0 net profit. The company is in pharmaceuticals, but with those numbers it is not an operating business; it is a shell-like entity carrying a book value and little else. ROE of 2.07% and ROCE of 1.00% are far below what I need from a compounder. A P/E of 20.11 on stagnated earnings is meaningless; you cannot value a company on a P/E when the profit number is negligible. The Piotroski score of 7/9 does catch my attention—it suggests the balance sheet has not deteriorated badly, and a price-to-book below 0.5 can create a margin of safety—but only if the stated book value can be realized. With a market cap of just ₹6 crore, this is a microcap with liquidity risk and no dividend to pay me while waiting. The PEG of 0.20 is a seductive number, but with zero growth, a low PEG is an illusion. Graham would demand evidence of profitability and management integrity. Promoter holding is unavailable, which is a red flag for a retail investor. This is not a business to own; it is a broken asset to monitor. I would not buy on hope. I need a catalyst—a return of sales, a restructuring, or a liquidation—before acting. Until then, it remains a possible asset play, not an investment.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer